Conditions

When metformin therapy fails in youth, alternatives are limited to human insulin and liraglutide.

Patients who have obesity but don't have diabetes may now reap the benefits of using a GLP-1 receptor agonist.

A woman, 72 years of age, type 2 diabetes, obesity, taking metformin, GLP1, ARB, and antidepressant (SSRI). Lost 20% total body weight in the past year. Recently complaining of dizziness and weakness. Glucose levels in the 60’s at home, at which time had symptoms of hypoglycemia. Glucose-lowering medications (metformin and GLP-1) were stopped. Continued to complain of dizziness and weakness especially in the morning.

A Mendelian Randomization found a correlation between type 2 diabetes and heart failure, utilizing genetic markers.

Loss of healthy behaviors due to depression may increase the risk of the development of type 2 diabetes.

Does early-onset type 2 diabetes put young patients at a higher risk of developing comorbidities as they become adults?

Can a new potential treatment combining an SGLT-2 and a GLP-1 RA mitigate cardiometabolic risk?

A VERTIS CV sub study showed significant improvements in glycemic control after adding ertugliflozin to insulin-based regimens.

According to two new studies, researchers have seen tremendous progress in delaying the onset of type one diabetes and slowing down the disease's progression.

American Diabetes Association mini-symposium presented by Mike Sampson, MD.